Nu-Med Plus (NUMD) Net Income towards Common Stockholders (2012 - 2025)
Nu-Med Plus (NUMD) reported Net Income towards Common Stockholders of -$12618.0 for Q4 2025, down 19.55% on a YoY basis from -$15683.3 in Q4 2024, and down 5.45% sequentially from -$11966.0 in Q3 2025.
Nu-Med Plus (NUMD) Net Income towards Common Stockholders (2012 - 2025) Analysis & Trends
Nu-Med Plus (NUMD) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$12618.0 in Q4 2025.
- For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 19.55% year-over-year to -$12618.0; the trailing twelve-month figure through Dec 2025 stood at -$56182.0 (up 17.8% YoY), and the FY2025 full-year result was -$56182.0, up 17.8% from the prior year.
- Net Income towards Common Stockholders retreated to -$12618.0 in Q4 2025, from -$11966.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $42606.0 in Q4 2022 to a low of -$2.2 million in Q4 2021.
- A 5-year average of -$164315.7 and a median of -$23073.0 in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders slumped 330.45% in 2021 and jumped 101.95% in 2022, its largest moves.
- Tracing NUMD's Net Income towards Common Stockholders over 5 years: stood at -$2.2 million in 2021, then jumped by 101.95% to $42606.0 in 2022, then slumped by 232.84% to -$56596.0 in 2023, then surged by 81.35% to -$10555.0 in 2024, then declined by 19.55% to -$12618.0 in 2025.
- Business Quant data shows NUMD's Net Income towards Common Stockholders at -$12618.0 in Q4 2025, -$11966.0 in Q3 2025, and -$11665.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.33 Bn | 174.04 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.11 Bn | 125.23 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.76 Bn | 98.54 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.95 Bn | 66.50 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 28.43 Bn | 26.14 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Dexcom | 28.31 Bn | 27.20 Bn | 750.30 Mn | 199.50 Mn |
| 8 | Smith & Nephew | 26.77 Bn | 26.19 Bn | - | - |
| 9 | Koninklijke Philips | 25.33 Bn | 22.21 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | -12,618.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12,618.00 |
| Sep 30, 2025 | -11,966.00 |
| Jun 30, 2025 | -11,665.00 |
| Mar 31, 2025 | -19,933.00 |
| Dec 31, 2024 | -10,555.00 |
| Sep 30, 2024 | -18,677.00 |
| Jun 30, 2024 | -17,287.00 |
| Mar 31, 2024 | -21,826.00 |
| Dec 31, 2023 | -56,596.00 |
| Sep 30, 2023 | -16,406.00 |
| Jun 30, 2023 | -24,320.00 |
| Mar 31, 2023 | -28,204.00 |
| Dec 31, 2022 | 42,606.00 |
| Sep 30, 2022 | -58,050.00 |
| Jun 30, 2022 | -58,070.00 |
| Mar 31, 2022 | -59,653.00 |
| Dec 31, 2021 | -2.19 Mn |
| Sep 30, 2021 | -118,366.00 |
| Jun 30, 2021 | -242,606.00 |
| Mar 31, 2021 | -356,748.00 |